시장보고서

상품코드

1722482

간질환 치료 시장 보고서 : 치료 유형, 질환 유형, 최종사용자, 지역별(2025-2033년)

Liver Disease Treatment Market Report by Treatment Type, Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, and Others), End User, and Region 2025-2033

발행일: 2025년 05월 | 리서치사:

IMARC | 페이지 정보: 영문 150 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 간질환 치료제 시장 규모는 2024년 251억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 404억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 5.44%를 보일 것으로 전망하고 있습니다. 간질환을 포함한 여러 만성 질환에 걸리기 쉬운 노인 인구가 전 세계적으로 증가하고 있는 것이 시장을 자극하고 있습니다.

간은 비타민과 영양소 저장, 혈액 내 유해물질 제거, 체내 화학물질의 적절한 균형 유지 등 중요한 기능을 수행하는 인체의 중요한 장기입니다. 암, 간염, 자가면역질환, 유전적 질환은 일반적인 간질환의 일부입니다. 이러한 질병은 일반적으로 감염, 유전, 비만, 당뇨병, 면역 체계의 이상으로 인해 발생합니다. 간질환의 치료법으로 널리 사용되는 것은 백신, 화학요법, 항바이러스제, 면역글로불린, 부신피질 스테로이드, 면역억제제 등이 있습니다. 간질환 치료는 콜레스테롤과 호르몬의 배설을 돕고 담즙의 생산과 효소의 활성화를 증가시킵니다.

간질환 치료제 시장 동향 :

간질환을 포함한 다양한 만성 질환에 취약한 노년층 인구가 전 세계적으로 증가하고 있는 것은 시장 성장을 가속하는 주요 요인 중 하나입니다. 식생활 패턴의 변화와 좌식 생활 습관이 시장 성장을 가속하고 있습니다. 또한, 고콜레스테롤, 비만, 고혈압, 당뇨병으로 인한 지방간질환의 유병률 증가는 시장 성장을 가속하고 있습니다. 또한, 바이오 인공간 개발 등 다양한 기술 발전이 시장 성장에 탄력을 받고 있습니다. 이는 재생 간세포를 이용하여 간 기능을 대체하는 것으로 급성 간부전 환자에게 널리 사용되고 있습니다. 이와 함께 안전하고 효과적이며 B형 간염 바이러스를 억제하고 간경변 및 간세포암 발병 위험을 감소시키는 항바이러스제의 급속한 보급이 시장 개척에 긍정적인 영향을 미치고 있습니다. 이와는 별도로 연구개발(R&D) 활동 증가, 헬스케어 산업의 괄목할만한 성장, 공중보건을 촉진하기 위한 다양한 정부 이니셔티브의 시행은 시장에 대한 밝은 전망을 만들어내고 있습니다.

본 보고서에서 다룬 주요 질문

2024년 세계 간질환 치료제 시장 규모는?
2025-2033년 세계 간질환 치료제 시장 성장률 전망은?
간질환 치료제 세계 시장을 이끄는 주요 요인은?
코로나19가 간질환 치료제 세계 시장에 미치는 영향은?
간질환 치료제 세계 시장에서의 치료 유형별 분류는?
간질환 치료제 세계 시장 내 질환별 분류는?
간질환 치료제 세계 시장을 최종 사용자별로 분류하면?
간질환 치료제 세계 시장 주요 지역은?
세계 간질환 치료제 시장의 주요 기업은?

북미
- 미국
- 캐나다
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 인도네시아
- 기타
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
라틴아메리카
- 브라질
- 멕시코
- 기타
중동 및 아프리카
- 시장 내역 : 국가별

제10장 SWOT 분석

개요
강점
약점
기회
위협

제11장 밸류체인 분석

제12장 Porter의 Five Forces 분석

개요
바이어의 교섭력
공급 기업의 교섭력
경쟁 정도
신규 진출업체의 위협
대체품의 위협

제13장 가격 분석

제14장 경쟁 구도

시장 구조
주요 기업
주요 기업 개요
- Abbott Laboratories
- AbbVie Inc.
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Viatris Inc.

LSH 25.05.29

The global liver disease treatment market size reached USD 25.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 40.4 Billion by 2033, exhibiting a growth rate (CAGR) of 5.44% during 2025-2033. The growing elderly population worldwide, which is prone to several chronic illnesses, including liver disease, is stimulating the market.

The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.

Liver Disease Treatment Market Trends:

The rising geriatric population, which is suspetible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the market. The changing dietary patterns and sedentary lifestyles are boosting the market growth. Additionally, the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is favoring the market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the market growth. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. In line with this, the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives to promote public health are creating a positive outlook for the market.

Key Market Segmentation:

Breakup by Treatment Type:

Antiviral Drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy

Breakup by Disease Type:

Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others

Breakup by End User:

Hospitals
Ambulatory Surgical Centers
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Viatris Inc.

Key Questions Answered in This Report

1.What was the size of the global liver disease treatment market in 2024?
2.What is the expected growth rate of the global liver disease treatment market during 2025-2033?
3.What are the key factors driving the global liver disease treatment market?
4.What has been the impact of COVID-19 on the global liver disease treatment market?
5.What is the breakup of the global liver disease treatment market based on the treatment type?
6.What is the breakup of the global liver disease treatment market based on the disease type?
7.What is the breakup of the global liver disease treatment market based on the end user?
8.What are the key regions in the global liver disease treatment market?
9.Who are the key players/companies in the global liver disease treatment market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Liver Disease Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Treatment Type

6.1 Antiviral Drugs
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Immunosuppressants
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Vaccines
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Immunoglobulins
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Corticosteroids
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Targeted Therapy
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
6.7 Chemotherapy
- 6.7.1 Market Trends
- 6.7.2 Market Forecast

7 Market Breakup by Disease Type

7.1 Hepatitis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Autoimmune Diseases
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Non-alcoholic Fatty Liver Disease (NAFLD)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Cancer
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Genetic Disorders
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast

8 Market Breakup by End User

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Ambulatory Surgical Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 AbbVie Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Astellas Pharma Inc.
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Bristol-Myers Squibb Company
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Eli Lilly and Company
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Emergent BioSolutions Inc.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 F. Hoffmann-La Roche AG
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
- 14.3.8 Gilead Sciences Inc.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 GlaxoSmithKline plc
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Merck & Co. Inc.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis
- 14.3.11 Novartis AG
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis
- 14.3.12 Pfizer Inc.
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio
  - 14.3.12.3 Financials
  - 14.3.12.4 SWOT Analysis
- 14.3.13 Sanofi S.A.
  - 14.3.13.1 Company Overview
  - 14.3.13.2 Product Portfolio
  - 14.3.13.3 Financials
  - 14.3.13.4 SWOT Analysis
- 14.3.14 Takeda Pharmaceutical Company Limited
  - 14.3.14.1 Company Overview
  - 14.3.14.2 Product Portfolio
  - 14.3.14.3 Financials
  - 14.3.14.4 SWOT Analysis
- 14.3.15 Viatris Inc.
  - 14.3.15.1 Company Overview
  - 14.3.15.2 Product Portfolio
  - 14.3.15.3 Financials